摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[7-[(2S,3S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-8-methoxy-2-oxochromen-3-yl]-4-methoxy-3-(3-methoxyphenyl)benzamide

中文名称
——
中文别名
——
英文名称
N-[7-[(2S,3S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-8-methoxy-2-oxochromen-3-yl]-4-methoxy-3-(3-methoxyphenyl)benzamide
英文别名
——
N-[7-[(2S,3S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-8-methoxy-2-oxochromen-3-yl]-4-methoxy-3-(3-methoxyphenyl)benzamide化学式
CAS
——
化学式
C33H35NO11
mdl
——
分子量
621.6
InChiKey
NWGWUYKYEZYKDX-PEXUEILESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    45
  • 可旋转键数:
    9
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    151
  • 氢给体数:
    3
  • 氢受体数:
    11

文献信息

  • Hsp90 activator Aha1 drives production of pathological tau aggregates
    申请人:University of South Florida
    公开号:US11318155B2
    公开(公告)日:2022-05-03
    Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    本文公开了抑制 Aha1 的化合物和方法,用于治疗牛头蛋白病和神经退行性疾病。Aha1 抑制剂可减少 Aha1 与 Hsp90 之间的相互作用。Aha1 抑制剂可减少 tau 蛋白的聚集。Aha1抑制剂可包括选自KU-177、KU-174和KU-308的化合物。
  • METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA
    申请人:Narain Niven Rajin
    公开号:US20140154266A1
    公开(公告)日:2014-06-05
    The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90β, expression and activity level.
  • THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES
    申请人:University of South Florida
    公开号:US20210128597A1
    公开(公告)日:2021-05-06
    Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
查看更多